Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas

Stopped The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial with a revised protocol.

Conditions

• Recurrent High-grade Glioma
• Recurrent Glioblastoma
• Recurrent Anaplastic Astrocytoma
• Recurrent Anaplastic Oligodendroglioma

Interventions

• RADIATION: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
• RADIATION: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq
• RADIATION: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq

Sponsor

Dawonmedax Co., Ltd.